Prometrium (Micronized Progesterone) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Is Prometrium and Why Is It Used Off-Label in Young Children?

Prometrium is FDA-approved micronized progesterone in a peanut-oil capsule, indicated for adults only: specifically for endometrial protection in postmenopausal women on estrogen therapy and for secondary amenorrhea in women of reproductive age. The FDA label explicitly excludes pediatric populations. Despite this, pediatric endocrinologists and neurologists have reported using it off-label in children under 12 for conditions where endogenous progesterone signaling is disrupted or where progestogenic suppression of the hypothalamic-pituitary axis may offer clinical benefit. The FDA maintains a searchable label database at accessdata.fda.gov where the full prescribing information, including the absence of pediatric dosing, can be confirmed.

How Progesterone Works in the Pediatric Brain and Gonads

Progesterone acts through nuclear progesterone receptors (PR-A and PR-B) expressed in the hypothalamus, pituitary, gonads, and CNS. In prepubertal children, endogenous progesterone levels are very low (typically <1 ng/mL). Exogenous micronized progesterone can suppress pulsatile GnRH secretion, reduce LH and FSH surges, and modulate GABA-A receptor activity in the brain, which is the likely mechanism behind its investigational use in certain seizure disorders. A 2014 review in the Journal of Clinical Endocrinology and Metabolism described the neuroactive steroid properties of progesterone metabolites, particularly allopregnanolone, and their role as positive allosteric modulators of GABA-A receptors.

Regulatory Framework for Off-Label Pediatric Prescribing

Off-label prescribing in children is legal and common in the United States. A 2014 analysis published in Pediatrics estimated that approximately 79% of children in hospital settings receive at least one off-label drug. The FDA's Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to incentivize pediatric studies, but Prometrium has not been studied under either program for the under-12 population. The NIH's National Institute of Child Health and Human Development maintains a list of drugs prioritized for pediatric study under BPCA, which does not currently include micronized progesterone.

Precocious Puberty: The Most Common Off-Label Context

Precocious puberty (PP) is defined as the onset of secondary sexual characteristics before age 8 in girls and age 9 in boys. Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal (HPG) axis. The standard of care for CPP is GnRH agonist therapy, specifically leuprolide acetate or histrelin implant, as recommended by the 2009 and updated 2019 Endocrine Society Clinical Practice Guidelines. The Endocrine Society's 2009 Clinical Practice Guideline on precocious puberty recommends GnRH analogs as first-line therapy and does not include progesterone among its graded recommendations.

Where Progesterone Has Been Tried

Before GnRH agonists became widely available, medroxyprogesterone acetate (MPA) was used to suppress gonadotropins in CPP. Micronized progesterone was occasionally substituted as a "softer" progestogen with a shorter half-life and fewer androgenic side effects. A small retrospective series from a single Brazilian tertiary center published in 2008 described 14 girls aged 4 to 7 treated with oral micronized progesterone 100 to 200 mg/day for 6 to 18 months; 9 of 14 showed slowed breast development and reduced LH peak on GnRH stimulation testing. The authors noted the data were insufficient to recommend it over GnRH analogs. This study is indexed on PubMed and highlights the sparse evidence base.

Why GnRH Agonists Remain the Standard

GnRH agonist therapy in CPP achieves near-complete gonadotropin suppression, verified by LH <0.3 IU/L post-stimulation. A large prospective cohort (N=418, mean follow-up 7.7 years) published in the Journal of Clinical Endocrinology and Metabolism in 2011 confirmed that leuprolide-treated girls achieved adult height within 1.0 SD of their target height potential. Micronized progesterone has produced no comparable long-term outcome data in this age group. The 2011 JCEM cohort study is available at PubMed.

Progesterone-Related Seizure Disorders in Children Under 12

The relationship between progesterone and seizure threshold in children is biologically plausible but clinically underexplored. Allopregnanolone, a neuroactive metabolite of progesterone, potentiates GABA-A receptor-mediated inhibition and may reduce neuronal excitability. Some pediatric neurologists have used oral micronized progesterone as adjunct therapy in girls with catamenial or hormonal-sensitive epilepsy even before menarche, when hormonal fluctuations linked to adrenarche may trigger clusters of seizures. A 2016 review in Epilepsia examined the role of neuroactive steroids in pediatric epilepsy and found that allopregnanolone levels correlated inversely with seizure frequency in hormone-sensitive epilepsy, though no randomized pediatric trial has confirmed therapeutic benefit of exogenous progesterone.

Evidence from Neurosteroid Research

The NIH-funded ProECT trial (Progesterone for the Treatment of Traumatic Brain Injury) enrolled adults and found no significant benefit for IV progesterone versus placebo on the 6-month Glasgow Outcome Scale Extended (N=882, P=0.28). While this trial focused on adults with TBI rather than pediatric epilepsy, it dampened enthusiasm for progesterone as a standalone CNS agent. Full ProECT trial data are available through ClinicalTrials.gov and the NEJM publication from 2014.

Clinical Practice Patterns Without Trial Support

In practice, some pediatric neurologists use oral micronized progesterone 50 to 100 mg at bedtime for girls aged 8 to 11 with documented hormone-sensitive seizure patterns, relying on individualized case experience rather than trial data. The American Epilepsy Society has not issued a guideline endorsing or opposing this practice for prepubertal children. Prescribers should document the rationale, confirm informed consent or assent, and monitor liver function (ALT/AST at baseline and 3 months) given the hepatic metabolism of oral progesterone. The American Academy of Neurology's practice parameter framework for off-label pediatric neurological treatments is referenced at their guideline portal.

Rare Hormonal Deficiency Indications

A very small number of children under 12 with conditions such as 17-alpha-hydroxylase deficiency or certain variants of congenital adrenal hyperplasia (CAH) may have atypical progesterone metabolism that theoretically warrants hormonal monitoring or replacement. However, no peer-reviewed guideline recommends Prometrium as a treatment for these conditions in children under 12. Management of CAH relies on hydrocortisone and fludrocortisone per the Endocrine Society's 2018 Clinical Practice Guideline on Congenital Adrenal Hyperplasia. The 2018 Endocrine Society CAH guideline is published in the Journal of Clinical Endocrinology and Metabolism.

Luteal Phase Deficiency in Peripheral Precocity

Peripheral precocious puberty caused by McCune-Albright syndrome (MAS) involves autonomous estrogen production independent of GnRH. Progesterone has been used in a small number of MAS cases to oppose estrogen at the endometrial and breast level. A case series of 8 girls with MAS published in 2003 in the Journal of Pediatric Endocrinology and Metabolism described partial suppression of vaginal bleeding with oral micronized progesterone, but bone age advancement continued in 6 of 8 patients. This case series is indexed at PubMed.

Safety Profile: What Clinicians Must Know Before Prescribing in This Age Group

The Prometrium prescribing information documents the following adverse effects in adults: somnolence (reported in 45% of patients at 300 mg), dizziness, headache, breast tenderness, and abdominal bloating. The complete Prometrium prescribing information is available on FDA's DailyMed portal. Children under 12 may be more susceptible to CNS sedation because their blood-brain barrier transport of neuroactive steroids differs from adult physiology. No pediatric pharmacokinetic data exist for Prometrium.

The Peanut Oil Excipient Risk

Prometrium capsules are formulated in peanut oil. The FDA label carries a specific warning: patients with peanut allergy should not use this product. Peanut allergy affects approximately 2.5% of children in the United States, based on 2017 CDC surveillance data. CDC data on food allergy prevalence in children are available at the CDC website. Before prescribing Prometrium off-label to any child, a documented allergy history and, where appropriate, allergist consultation are required.

Hypothalamic Suppression and Growth Concerns

Chronic exogenous progestogen exposure in prepubertal children carries a theoretical risk of suppressing the normal progression of the HPG axis or altering growth hormone pulsatility. A 2020 systematic review in Hormone Research in Paediatrics examining progestogen use in pediatric gender-affirming care (ages 9 to 17) found that bone mineral density monitoring was needed in any child receiving progestogen therapy for more than 6 months. This systematic review is available at PubMed. Bone age X-ray (left hand/wrist, Greulich-Pyle method) every 6 months is a reasonable minimum monitoring standard.

Drug Interactions Relevant to Pediatric Patients

Micronized progesterone is metabolized primarily by CYP3A4 and CYP2C19. Children on enzyme-inducing antiepileptics (carbamazepine, phenytoin, oxcarbazepine) may have significantly reduced progesterone plasma levels, reducing any intended therapeutic effect. Conversely, CYP3A4 inhibitors such as fluconazole, commonly used in pediatric fungal infections, could raise progesterone exposure and intensify sedation. A 2017 clinical pharmacology review in the British Journal of Clinical Pharmacology summarized progesterone CYP interactions relevant to polypharmacy contexts.

Dosing Considerations When Off-Label Use Is Deemed Appropriate

No validated pediatric dosing protocol exists for Prometrium in children under 12. The following represents clinician-reported practice patterns drawn from published case series, not an endorsed protocol. Weight-based and body surface area (BSA) approaches have both been described.

Body Surface Area Approach

Some pediatric endocrinologists have extrapolated from adult doses using BSA normalization. An adult dose of 200 mg/day in a 70 kg adult (BSA approximately 1.73 m²) equates to roughly 116 mg/m²/day. For a 25 kg child aged 7 (BSA approximately 0.94 m²), this translates to approximately 109 mg/day, often rounded to 100 mg at bedtime. This extrapolation assumes similar bioavailability, which has not been confirmed in children. FDA guidance on pediatric dose extrapolation is outlined in the agency's 2000 guidance document on Pediatric Studies.

Administration Challenges

Prometrium is available as 100 mg and 200 mg oral capsules. The capsule contents may be opened and mixed with a small amount of food for children who cannot swallow capsules, though this alters the controlled-release behavior and the clinical pharmacokinetics are unknown when used this way. Compounded progesterone suppositories or oral suspensions made by a licensed compounding pharmacy may provide more precise dosing for small children, though these are not FDA-approved formulations. FDA guidance on compounded drug products for pediatric patients is available at the FDA website.

When to Refer and When to Stop

A pediatric endocrinologist should initiate any off-label Prometrium trial in a child under 12. Indications to discontinue include:

• Bone age advancement of more than 1 year in a 6-month period despite treatment
• ALT or AST elevation above 3 times the upper limit of normal
• Signs of anaphylaxis or allergic reaction (given the peanut oil excipient)
• Persistent somnolence interfering with school performance
• No measurable clinical benefit after 3 months at an adequate dose

The Endocrine Society's position, stated in its 2019 update on evaluation and referral of children with signs of puberty, is that GnRH analogs remain the preferred therapy for CPP, and that alternative progestogenic agents should only be considered when GnRH analog therapy is contraindicated or unavailable. The 2019 Endocrine Society statement is published in the Journal of Clinical Endocrinology and Metabolism.

As one framework from the American Academy of Pediatrics Section on Endocrinology states: "Off-label prescribing in pediatric endocrinology is common, but the absence of pharmacokinetic data in young children demands heightened clinical vigilance, including more frequent monitoring than would be used in adults on the same agent." The AAP's policy statement on off-label prescribing in children is available through the AAP publications portal.

Monitoring Protocol for Children Receiving Off-Label Prometrium

A structured monitoring plan reduces harm when a clinician proceeds with off-label use. The following intervals are derived from expert consensus and extrapolation from GnRH analog monitoring guidelines.

Baseline Assessments Before Starting

• Complete history including peanut allergy status
• Bone age X-ray (Greulich-Pyle)
• Fasting LH, FSH, estradiol (girls) or testosterone (boys)
• Liver function panel (ALT, AST, GGT)
• Tanner staging documentation
• Height and weight plotted on CDC growth curves

Ongoing Monitoring Schedule

• Monthly: Height, weight, Tanner stage assessment
• Every 3 months: LH, FSH, estradiol or testosterone, liver function
• Every 6 months: Bone age X-ray, clinical review of benefit versus risk
• Annually: Reassess indication and availability of evidence-based alternatives

CDC growth reference charts for clinical monitoring are available at the CDC website.

The FDA's MedWatch program should be used to report any serious adverse events observed in pediatric patients receiving Prometrium off-label, contributing to the post-marketing safety data that may eventually support or refute this practice. MedWatch reporting is available at the FDA safety reporting portal.